GLP-1 Shaming: Why Treating Obesity Medically Isn't 'Cheating' — It's Science
Published by New Jersey Trim Clinic · Updated 2025-05-07
Using GLP-1 Medication Is Not Cheating — It's Science
There is a growing social trend around GLP-1 medications that has little to do with medicine and everything to do with stigma.
Words like "cheating," "lazy," "the easy way out," and "just eat less" circulate widely online.
At the same time, obesity remains one of the leading contributors to cardiovascular disease, type 2 diabetes, stroke, fatty liver disease, sleep apnea, and reduced life expectancy worldwide.
So let's address this honestly — and clinically.
Obesity Is Not a Willpower Disorder
In 2013, the American Medical Association officially recognized obesity as a disease. The World Health Organization and multiple endocrine societies classify obesity as a chronic, relapsing metabolic condition.
Why does that matter? Because diseases are treated.
We do not tell people with asthma to "breathe harder." We do not tell people with high blood pressure to "relax more." We do not shame someone for using an inhaler or insulin. We treat the biology.
Obesity is driven by hormonal signaling, brain reward pathways, insulin resistance, metabolic adaptation, genetic predisposition, and environmental exposure. Reducing it to "discipline" ignores decades of endocrinology research.
The Biology of Hunger
When someone loses weight, the body does not cooperate. Research from Leibel et al. in the New England Journal of Medicine demonstrated that after weight loss, resting metabolic rate decreases, energy efficiency increases, hunger hormones rise, and satiety hormones fall.
This is called metabolic adaptation.
In practical terms, the body fights weight loss. Ghrelin (the hunger hormone) increases. Leptin (the fullness hormone) decreases. Food becomes more rewarding neurologically.
This is not weakness. It is physiology.
For many individuals with moderate to severe obesity, this adaptive response makes sustained 15-20% weight loss through lifestyle alone biologically difficult. That reality is not moral. It is scientific.
What GLP-1 Medications Actually Do
GLP-1 receptor agonists mimic a natural gut hormone that regulates appetite and insulin response. They slow gastric emptying, increase insulin secretion in response to glucose, suppress glucagon, reduce central appetite signaling, and decrease reward activation in response to high-calorie foods.
In clinical trials, semaglutide produced approximately 15% average weight loss (STEP-1, NEJM 2021). Tirzepatide produced up to 20% average weight loss (SURMOUNT-1, NEJM 2022). These are outcomes previously seen primarily with bariatric surgery.
This is not cosmetic weight loss. This is metabolic treatment.
Why the "Easy Way Out" Argument Falls Apart
No one describes chemotherapy as "the easy way out." No one calls statins "cheating." No one accuses someone of laziness for using CPAP for sleep apnea.
But obesity has been culturally moralized.
GLP-1 therapy does not eliminate effort. Patients still modify diet, improve protein intake, increase resistance training, monitor behaviors, and manage sleep. The medication regulates appetite. It does not remove responsibility. It removes the constant biological headwind.
The Courage Factor
For many individuals, starting GLP-1 therapy is not vanity-driven. It is health-driven.
The SELECT trial (2023) showed that semaglutide reduced major adverse cardiovascular events in individuals with overweight or obesity without diabetes. That is not cosmetic benefit. That is morbidity reduction.
Choosing treatment to reduce heart attack risk is not weakness. It is proactive healthcare.
Why Shaming Is Clinically Counterproductive
Weight stigma itself is associated with increased stress hormones, emotional eating, avoidance of medical care, and higher long-term weight gain.
Stigma does not improve health outcomes. It worsens them. When patients are shamed, they delay treatment. When patients are supported, they engage.
The Balanced Truth
GLP-1 medications are not for everyone. They require medical supervision. They have side effects. They require long-term planning.
But using evidence-based treatment for a recognized chronic disease is not cheating. It is informed healthcare.
If we normalize insulin for diabetes, inhalers for asthma, and statins for cholesterol, we can normalize medically supervised obesity treatment.
The goal is not appearance. The goal is metabolic health, longevity, and quality of life. And seeking that is not weakness. It is strength.
New Jersey Patients: You Deserve Support, Not Judgment
At New Jersey Trim Clinic, we do not judge. We treat. Physician-supervised GLP-1 programs via telehealth — $149/month, all-inclusive, no membership fees. Whether you are in Bergen County, Camden, Trenton, or the Shore, you can start your journey from home.
Read more about GLP-1 science and patient advocacy at our Patient Education Library: www.eliminatethefoodnoiseinyourhead.com
*This article is adapted from our Patient Education Library. Original article: "GLP-1 Shaming: Why Treating Obesity Medically Isn't 'Cheating' — It's Science." References include the American Medical Association (2013), Leibel et al. (NEJM 1995), van Bloemendaal et al. (Diabetes 2014), Wilding et al. (NEJM 2021), Jastreboff et al. (NEJM 2022), and the SELECT Trial Investigators (NEJM 2023).*
*Individual results vary. Treatment is only prescribed after evaluation by a licensed medical provider. No specific amount of weight loss is guaranteed.*